Login to Your Account



FDA clears Gilead’s Sofosbuvir in HCV; Simeprevir combo ‘door open’?

By Randy Osborne
Staff Writer

Friday, December 6, 2013
As expected, the FDA approved Gilead Sciences Inc.’s Sovaldi (sofosbuvir) 400-mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for chronic hepatitis C virus, as part of a combination antiviral treatment regimen.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription